Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C5NP
|
||||
| Former ID |
DND000036
|
||||
| Drug Name |
AGG-523
|
||||
| Synonyms |
PF-5212371, WAY-266523
|
||||
| Indication | Osteoarthritis [ICD9: 715; ICD10:M15-M19, M47] | Phase 1 | [1] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Aggrecanase | Target Info | Inhibitor | [2] | |
| Reactome | Degradation of the extracellular matrix | ||||
| O-glycosylation of TSR domain-containing proteins | |||||
| WikiPathways | Endochondral Ossification | ||||
| Vitamin D Receptor Pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00454298) Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement. U.S. National Institutes of Health. | ||||
| REF 2 | Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011 Mar;19(3):315-23. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.